Ozempic and Wegovy: Could Weight Loss Jabs Soon Cost Just $3 a Month?
A potential revolution in global health is on the horizon. New research suggests that the cost of semaglutide – the active ingredient in popular weight loss medications like Wegovy and Ozempic – could plummet to as little as $3 per monthly dose. This dramatic price reduction could unlock access to these life-changing drugs for millions currently priced out of the market, particularly in lower-income countries.
The Obesity Crisis: A Growing Global Challenge
More than a billion people worldwide live with obesity, and rates are rapidly increasing in nations adopting Westernized diets and more sedentary lifestyles. The World Health Organization (WHO) designated semaglutide as an essential medicine in September 2025, recognizing its potential to address this escalating public health crisis. However, high prices have remained a significant barrier to widespread access.
Patent Expiration and Generic Competition
The prospect of significantly lower prices hinges on the expiration of key patents on semaglutide. These patents are set to expire in 10 countries this year, including Brazil, China, India, South Africa, Turkey, Mexico, and Canada, paving the way for generic manufacturers to enter the market. Crucially, researchers identified an additional 150 countries where patents haven’t even been filed, representing a vast potential for affordable access. These 160 countries are home to 69% of people with type 2 diabetes and 84% of those living with obesity.
How Low Could Prices Go?
The new research, published as a pre-print, estimates that mass production could bring the cost of an injectable monthly dose of semaglutide down to $3. Newer pill formulations could be manufactured for around $16 a month. This analysis builds on previous findings from Médecins Sans Frontières, which also highlighted the potential for significantly cheaper production of diabetes drugs, including semaglutide.
A Model for Success: Lessons from HIV, TB, and Malaria
Experts are drawing parallels to the success stories of HIV, tuberculosis, malaria, and hepatitis treatments. These medications are now available in low- and middle-income countries at prices close to the cost of production, saving millions of lives while still allowing generic companies to operate profitably. “We can repeat this medical success story for semaglutide,” says Prof François Venter from Witwatersrand University in Johannesburg.
Beyond Price: Addressing the Root Causes of Obesity
While lower prices are a critical step, researchers caution that they won’t solve the obesity crisis alone. Addressing the underlying structural drivers – including food insecurity, poverty, urbanization, and the prevalence of ultra-processed foods – is equally important. Coordinated policies and procurement planning will be essential to maximize the benefits of increased affordability.
Impact on Low- and Middle-Income Countries
The potential impact on countries like South Africa and others in Africa is particularly significant. Dr. Nomathemba Chandiwana, chief scientific officer at South Africa’s Desmond Tutu Health Foundation, notes that cost has been a major obstacle to access. Analysis suggests that approximately 27% of adults globally could benefit from drugs like semaglutide, with the majority residing in low- and middle-income countries.
Frequently Asked Questions
- What is semaglutide? Semaglutide is the active ingredient in medications like Ozempic and Wegovy, used to treat type 2 diabetes and obesity.
- How much do Ozempic and Wegovy currently cost? Currently, Ozempic and Wegovy can cost around $200 a month in the US and £120 a month in the UK.
- When will the patents on semaglutide expire? Patents are expiring in 10 countries in 2026, and have not been filed in 150 others.
- What is the WHO’s role in this? The WHO designated semaglutide as an essential medicine and is advocating for increased access and affordability.
Pro Tip: Keep an eye on developments regarding generic drug approvals in your country. This will be a key indicator of when lower-cost options grow available.
The potential for affordable semaglutide represents a major step forward in the fight against obesity and its associated health risks. However, realizing this potential will require a concerted effort from governments, health systems, and pharmaceutical companies to ensure equitable access for all who could benefit.
